D.A. Davidson & CO. Sells 2,003 Shares of Sanofi $SNY

D.A. Davidson & CO. lessened its stake in shares of Sanofi (NASDAQ:SNY) by 29.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,907 shares of the company’s stock after selling 2,003 shares during the period. D.A. Davidson & CO.’s holdings in Sanofi were worth $237,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of SNY. Brighton Jones LLC raised its stake in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Sanofi by 58.7% during the first quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock valued at $336,000 after acquiring an additional 2,241 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Sanofi by 1.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 33,328 shares of the company’s stock valued at $1,848,000 after acquiring an additional 318 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Sanofi by 570.6% during the first quarter. Bessemer Group Inc. now owns 4,339 shares of the company’s stock valued at $240,000 after acquiring an additional 3,692 shares in the last quarter. Finally, Golden State Wealth Management LLC raised its stake in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after acquiring an additional 545 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

NASDAQ SNY opened at $50.94 on Friday. The firm’s fifty day simple moving average is $48.71 and its two-hundred day simple moving average is $49.56. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The firm has a market capitalization of $125.08 billion, a P/E ratio of 11.93, a P/E/G ratio of 1.38 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.10. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $14.53 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same period in the previous year, the company earned $2.25 earnings per share. The business’s revenue for the quarter was down 7.5% on a year-over-year basis. Analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the subject of several research analyst reports. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.